Navigation Links
Pharma Product Commercialization: Standardized Team Processes Help Save Complex Drug Launches
Date:1/31/2008

CHAPEL HILL, N.C., Jan. 31 /PRNewswire/ -- The new product development process is exceedingly complex. It spans many years, involves multitudes of people, and consumes hundreds of millions of dollars in capital resources. Not surprisingly, one pharmaceutical marketing executive noted: "This process is so complex that no single person in the organization actually knows how all the parts work."

For this reason, benchmark partners emphasize the importance of standardizing the new-product development process while implementing strong cross-functional launch teams. This team's role of shaping the compound into a successful product is just as important as the biological attributes of the compound. With standardization, individuals and teams can better understand where and how to introduce market insights into the long-spanning commercialization process.

The report, "Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence," delivers proven practices that best-in-class firms use to enable and manage effective cross-functional teams, such as empowering launch teams to make key decisions and team members following well- established, standardized processes.

Download a complimentary study summary at http://www3.best-in-class.com/rr906.htm.

Learn from industry leaders, including Amgen, AstraZeneca, Bayer, Eli Lilly GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Wyeth. Executives in pharma and biotech companies can use this research to build and manage strong launch teams that can excel across functions, units and regions.

High-performing systems find many places and methods to introduce standardization into commercialization activities, for example:
-- Conduct strategy meetings to forge consensus between Strategic

Marketing, Decision Analytics, R&D, Regulatory, Finance

-- Model markets for R&D and marketing organizations

-- Prioritize product lists using qualitative and quantitative

methodologies (NPVs, performance criteria scorecards)

-- Conduct therapeutic area-specific CI

-- Develop portfolio valuations that embed commercial perspectives in the

valuation process

-- Provide input for clinical trial design and desired clinical outcomes

-- Conduct product risk analyses

Download additional process excellence tactics and best practices for building successful cross-functional teams in the study summary at: http://www3.best-in-class.com/rr906.htm.

This benchmarking report highlights the following areas of cross- functional team management:
-- Cross-Functional Team Structures

-- Collaboration and Productivity Processes

-- People Management

-- Decision-Making Processes

-- Communication and Collaboration

-- Resource Allocation

For more information contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... and setting the stage for new clinical and scientific initiatives have all marked ... after she was appointed President and CEO of the nation’s oldest cancer center, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... At ... election of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott ... Chairman of the Board,” stated Leslie A. Chambers , APDA President and CEO. ...
(Date:2/5/2016)... ... 2016 , ... In sleep, when the defenses of the day are at ... patients with eating disorders is significant self-criticism, and consequently these patients experience this disease ... as maladaptive means for coping with this unease, but also leads to a reservoir ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
(Date:2/4/2016)... 4, 2016 For hospitals considering enrollment in ... participating in the program, the Health Resources and Services ... the , Mega-Guidance , could have significant impact on ... in September 2016. Essential Insights , ... , summarizes the Mega-Guidance,s key proposed changes, including a ...
Breaking Medicine Technology: